---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-21-000032"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:21:00.079121+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics reports Q2 2021 cash of $263.5M; pipeline advancing

## Summary
- Cash, equivalents, and investments $263.5M as of June 30, 2021; expected to fund operations into 2023.
- R&D expenses $26.7M vs $10.2M in Q2 2020; net cash used in operations $49.6M.
- BDTX-189 Phase 1 data presented at ASCO; Phase 2 initiation on track for H2 2021 after FDA dialogue.
- IND filings planned: BDTX-1535 in H1 2022, BRAP and FGFR programs in 2022.
- Appointed Elizabeth Buck as CSO, Karsten Witt as interim CMO; Drs. Humphrey and Roberts departed; Mark Velleca added to Board.

## SEC filing metadata
- accession: 0001701541-21-000032
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000032/0001701541-21-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154121000032/bdtx-20210812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-21-000032
- JSON: https://secwatch.observer/filing/0001701541-21-000032.json
- Plain text: https://secwatch.observer/filing/0001701541-21-000032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.